Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
Public ClinicalTrials.gov record NCT00522145. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of XL647 in Subjects With Non-Small Cell Lung Cancer Who Have Progressed After Responding to Treatment With Either Gefitinib or Erlotinib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the best confirmed response rate of daily administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with either erlotinib or gefitinib.
Study identification
- NCT ID
- NCT00522145
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 41 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2007
- Primary completion
- Sep 30, 2009
- Completion
- Jan 31, 2010
- Last update posted
- May 12, 2022
2007 – 2010
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ronald Yanagihara | Gilroy | California | 95020 | — |
| University of California Davis Cancer Center | Sacramento | California | 95817 | — |
| Oncology Division and General Clincial Research, Stanford University Medical Center | Stanford | California | 94305 | — |
| Cancer Care Center, Inc. P.C. | New Albany | Indiana | 47150 | — |
| Washington County Hospital, The Center for Clinical Research | Hagerstown | Maryland | 21740 | — |
| Wayne State University, Wertz Clinical Cancer Center, Karmanos Center | Detroit | Michigan | 48201 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| New Bern Cancer Care Oncology | New Bern | North Carolina | 28560 | — |
| Case Western Reserve University, University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Signal Point Clinical Research Center | Middletown | Ohio | 45042 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00522145, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 12, 2022 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00522145 live on ClinicalTrials.gov.